Recombinant antibodies for the detection and neutralization of anthrax toxin
AssigneeBoard of Regents, The University of Texas System
InventorsGeorge Georgiou, Brent L. Iverson, Jennifer A. Maynard
Life of this patent
Estimating the term…
Abstract
A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.
Claims16
A purified affinity-matured antibody or a portion thereof having binding specificity for 83 kDa protective antigen (PA83) of Bacillus anthracis, wherein the affinity-matured antibody or the portion thereof exhibits an equilibrium dissociation constant of between 12 nM and 0.25 nM as measured by surface plasmon resonance, and wherein the affinity-matured antibody or the portion thereof confers protection to a host against a tripartite toxin of Bacillus anthracis.
A purified affinity-matured antibody or a portion thereof having binding specificity for 83 kDa protective antigen (PA83) of Bacillus anthracis, wherein the affinity-matured antibody or the portion thereof exhibits an equilibrium dissociation constant of between 4 nM and 0.25 nM as measured by surface plasmon resonance, and wherein the affinity-matured antibody or the portion thereof confers protection to a host against a tripartite toxin of Bacillus anthracis.
A purified affinity matured scFv comprising SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.